Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection

Journal of Heart and Lung Transplantation

Volumn 18, Issue 12, 1999, Pages 1224-1227

  Park, Myung H ^a   Starling, Randall C ^b   Ratliff, Norman B ^b   McCarthy, Patrick M ^b   Smedira, Nicholas S ^b   Pelegrin, David ^b   Young, James B ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; PREDNISONE; STEROID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; COSTS AND COST ANALYSIS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PULSE THERAPY, DRUG; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032740704     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(99)00098-4     Document Type: Article

References (23)

1. O'Connell J.B., Renlund D.G. Variations in the diagnosis, treatment, and prevention of cardiac allograft rejection the need for standardization? J Heart Transplant. 9:1990;269.
2. Griepp R.G., Stinson E.B., Dong E., Clarck D.A., Shumway N.E. Determinants of operative risk in human heart transplantation. Am J Surg. 122:1971;192.
3. Fragomeni L.S., Kaye M.P. The registry of the International Society for Heart Transplantation fifth official report - 1988 . J Heart Transplant. 7:1988;249.
4. Mishka P.T., Bates L.R., Collins C.L., Bolling S.F., Deeb G.M. Methylprednisolone pulsing of heart transplant patients in the home. J Heart Transplant. 7:1988;353.
5. Haverich A., Frimpong-Boateng K., Schafers H.J., et al. Individualized immunosuppression in heart transplant recipients. Transplant Proc. 19:1987;2514.
6. Renlund D.G., O'Connell J.B., Gilbert E.M., Watson F.S., Bristow M.R. Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. J Heart Transplant. 6:1987;71.
7. Wahlers T., Heublein B., Cremer J., et al. Treatment of rejection after heart transplantation What dosage of pulsed steroid is necessary? J Heart Transplant. 9:1990;568.
8. Miller L.W. Treatment of cardiac allograft rejection with intravenous corticosteroids. J Heart Transplant. 9:1990;283.
9. Michler RE, Smith CR, Drusin RE, et al. Reversal of cardiac transplant rejection without massive immunosuppression. Circulation 1986;74(suppl III):III-68.
10. Kobashigawa J.A., Stevenson L.W., Moriguchi J.D., et al. Is intravenous glucocorticoid therapy better than oral regimen for asymptomatic cardiac rejection? A randomized trial. J Am Coll Cardiol. 21:1993;1142.
11. Hosenpud J.D., Norman D.J., Pantley G.A. Low-dose oral prednisone in the treatment of acute cardiac allograft rejection not associated with hemodynamic compromise. J Heart Transplant. 9:1990;292.
12. Billingham M.E., Cary N.R.B., Hammond M.E., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection heart rejection study group . J Heart Transplant. 9:1990;587.
13. Hosenpud J.D., Bennett L.E., Keck B.M., et al. The registry of the International Society for Heart and Lung Transplantation Fourteenth Official Report - 1997 . J Heart Lung Transplant. 16:1997;691.
14. Munchmore J.S., Cooper D.K.C., Ye Y., et al. Prevention of loss of vertebral bone density in heart transplant patients. J Heart Lung Transplant. 11:1992;959.
15. Baylink D.J. Glucocorticoid-induced osteoporosis. N Engl J Med. 309:1983;306.
16. Prieto M., Lake K.D., Pritzker M.R., et al. OKT3 inductions and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients. J Heart Lung Transplant. 10:1991;901-911.
17. Keogh A., Macdonald P., Harvison A., et al. Initial steroid-free versus steroid-based maintenance therapy and steroid withdrawal after heart transplantation two views of the steroid question . J Heart Lung Transplant. 11:1992;421-427.
18. Kemma M.S., Valentine H.A., Hunt S.A., et al. Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J. 128:1994;68-72.
19. El-Gamel A., Doran H., Rahman A., et al. Clinical importance of Grade 2 cellular heart rejection. J Heart Lung Transplant. 15:1996;319.
20. Radovancevic B., Birovljev S., Frazier O.H. Treating cardiac allograft rejection present approach-analysis of 100 consecutive patients . J Heart Transplant. 9:1990;288.
21. Kobashigawa J.A. Treatment of nonhemodynamic compromising rejection conventional approaches vs. individualization/new immunosuppressive drugs . Transplant Proceed. 29:1997;37S-39S.
22. Wahlers T., Cremer J., Fieguth H.G., et al. Short-term boost of oral steroids for treatment of acute rejection following cardiac transplantation. Bibl Cardiol. 43:1988;19.
23. Winters G.L., Loh E., Schoen F.J. Natural history of focal moderate cardiac allograft rejection. Is treatment warranted? Circulation. 91:1995;1975.